Data on Doxorubicin Therapy Reported by Researchers at Case Western Reserve University (On-Command Drug Release from Nanochains Inhibits Growth of Breast Tumors)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Drugs and Therapies. According to news reporting out of Cleveland, Ohio, by NewsRx editors, research stated, "To evaluate the ability of radiofrequency (RF)-triggered drug release from a multicomponent chain-shaped nanoparticle to inhibit the growth of an aggressive breast tumor. A two-step solid phase chemistry was employed to synthesize doxorubicin-loaded nanochains, which were composed of three iron oxide nanospheres and one doxorubicin-loaded liposome assembled in a 100-nm-long linear nanochain."
Our news journalists obtained a quote from the research from Case Western Reserve University, "The nanochains were tested in the 4T1-Luc-GFP orthotopic mouse model, which is a highly aggressive breast cancer model. The 4T1-Luc-GFP cell line stably expresses firefly luciferase, which allowed the non-invasive in vivo imaging of tumor response to the treatment using bioluminescence imaging (BLI). Longitudinal BLI imaging showed that a single nanochain treatment followed by application of RF resulted in an at least 100-fold lower BLI signal compared to the groups treated with nanochains (without RF) or free doxorubicin followed by RF. A statistically significant increase in survival time of the nanochain-treated animals followed by RF (64.3 days) was observed when compared to the nanochain-treated group without RF (35.7 days), free doxorubicin-treated group followed by RF (38.5 days), and the untreated group (30.5 days; n = 5 animals per group)."
According to the news editors, the research concluded: "These studies showed that the combination of RF and nanochains has the potential to effectively treat highly aggressive cancers and prolong survival."
For more information on this research see: On-Command Drug Release from Nanochains Inhibits Growth of Breast Tumors. Pharmaceutical Research, 2014;31(6):1460-1468. Pharmaceutical Research can be contacted at: Springer, Plenum Publishers, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Pharmaceutical Research - www.springerlink.com/content/0724-8741/)
Our news journalists report that additional information may be obtained by contacting P.M. Peiris, Case Western Reserve University, Case Comprehens Canc Center, Cleveland, OH 44106, United States. Additional authors for this research include M. Tam, P. Vicente, A. Abramowski, R. Toy, L. Bauer, A. Mayer, J. Pansky, E. Doolittle, S. Tucci, E. Schmidt, C. Shoup, S. Rao, K. Murray, R. Gopalakrishnan, R.A. Keri, J.P. Basilion, M.A. Griswold and E. Karathanasis (see also Drugs and Therapies).
Keywords for this news article include: Ohio, Antibiotics - Antineoplastics, Pharmaceuticals, Cleveland, United States, Drugs and Therapies, North and Central America, Doxorubicin Hydrochloride
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC